Sangamo Biosciences Director Sells $125,600 in Stock (SGMO)
Sangamo Biosciences (NASDAQ:SGMO) Director John William Larson sold 10,000 shares of the stock in a transaction that occurred on Monday, August 4th. The shares were sold at an average price of $12.56, for a total value of $125,600.00. Following the sale, the director now directly owns 218,160 shares of the company’s stock, valued at approximately $2,740,090. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.
Shares of Sangamo Biosciences (NASDAQ:SGMO) traded up 5.59% during mid-day trading on Tuesday, hitting $13.60. The stock had a trading volume of 1,519,629 shares. Sangamo Biosciences has a 52 week low of $8.93 and a 52 week high of $24.69. The stock has a 50-day moving average of $14.04 and a 200-day moving average of $16.19. The company’s market cap is $927.0 million.
Sangamo Biosciences (NASDAQ:SGMO) last posted its quarterly earnings results on Wednesday, July 23rd. The company reported ($0.10) earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.14) by $0.04. The company had revenue of $10.38 million for the quarter, compared to the consensus estimate of $7.84 million. During the same quarter last year, the company posted ($0.10) earnings per share. Sangamo Biosciences’s revenue was up 50.4% compared to the same quarter last year. Analysts expect that Sangamo Biosciences will post $-0.26 EPS for the current fiscal year.
Separately, analysts at JPMorgan Chase & Co. initiated coverage on shares of Sangamo Biosciences in a research note on Friday. They set an “overweight” rating and a $22.00 price target on the stock. One research analyst has rated the stock with a hold rating and three have issued a buy rating to the company. The company currently has an average rating of “Buy” and an average target price of $22.92.
Sangamo BioSciences, Inc is a clinical stage biopharmaceutical company. The Company is engaged in the research, development and commercialization of zinc finger deoxyribonucleic acid (NASDAQ:SGMO)-binding proteins (ZFPs), a naturally occurring class of proteins.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.